Kailera obesity pill HRS-7535 hits endpoint in Chinese Phase 3
Nausea was reported by 70% of recipients and vomiting by 67% to 69%, rates a William Blair analyst called alarming.
PR
By Priya Raman · Science Reporter
Jul 7 03:00 ETSource: BioPharma Dive
The wire
- 01Kailera and partner Hengrui said the oral GLP-1 HRS-7535 produced about 10% weight loss over 10 months in a Phase 3 trial conducted in China.
- 02For comparison, the Wegovy pill delivered roughly 14% weight loss at 64 weeks and Lilly's Foundayo about 11% at 72 weeks, though Chinese trials typically enroll lower-BMI and more male participants.
- 03No signs of liver toxicity appeared, a concern given structural similarity to Pfizer's shelved danuglipron; a global Phase 2 is testing lower and nighttime dosing, and a longer global trial is still needed.
From the source
Read at biopharmadive.comKailera says obesity pill succeeds in late-stage trial in China
The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.
